对B-NHL淋巴瘤相关基因突变联合检测的研究
Chinese Journal of Birth Health & Heredity(2008)
Abstract
目的探讨联合检测IgH基因单克隆性重排带及BCL-2IgH(MBR)融合基因,对B-NHL淋巴瘤诊断及化疗前、后微小残留灶克隆性变化监测的意义。方法采用上述两种靶基因突变检测的PCR方法各两种,检测B-NHL组患者及非淋巴瘤肿瘤组患者各30例,观察化疗前、后的检出阳性率及变化,同时设健康对照30例。结果联合两种方法对B-NHL淋巴瘤治疗前患者WBC基因组DNA中的IgH基因96·6%呈单克隆重排带,化疗后原来单克隆重排带者有1例转阴,2例转为2克隆性,2例转为3克隆性;两组对照阴性。B-NHL淋巴瘤患者中38·3%BCL-2/IgH(MBR)融合基因阳性,非淋巴瘤肿瘤组患者为10·0%,健康人为6·6%;联合两种方法对B-NHLBCL-2IgH(MBR)的总检出阳性率为38·3%。结论联合检测IgH基因重排及BCL-2/IgH(MBR)融合基因可提高B-NHL的诊断率,IgH基因单克隆重排带在B-NHL,化疗前后检测对监测B-NHL微小残留灶克隆性变化有一定意义。
MoreTranslated text
Key words
Combined gene diagnosis,B-NHL,Gene rearangement
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined